search
Back to results

Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies (EMLFO-2)

Primary Purpose

Prematurity, Intestine Perforation, Necrotizing Enterocolitis (NEC)

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Microlipid with fish oil
Microlipid
Sponsored by
Wake Forest University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Prematurity focused on measuring NEC, SBS, enterostomy, fish oil, Microlipid, Intralipid,, enteral fat

Eligibility Criteria

1 Day - 2 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. infants (age range: newborn to ≤ 2-month-old) whose birth weight are ≤ 1250g;
  2. who are admitted to BCH NICU for surgical intervention for NEC or small intestine perforation and then to have a jejunostomy or ileostomy;
  3. who are expected to need full or partial PN for at least 21days from the day of ostomy placement; and
  4. who have received enteral feedings ≤ 4 days since ostomy placement.

Exclusion Criteria:

  1. infant with birth weight > 1250g;
  2. infant with colostomy;
  3. infants with enterostomy but

    • unable to obtain written informed consent from parent;
    • presence of congenital liver, renal, or metabolic diseases or syndromes or perinatal asphyxia;
    • ostomy caused by surgical treatment for a condition other than NEC or small intestine perforation; and
    • unable to initiate enteral feeding for more than 28 days since ostomy placement.

Sites / Locations

  • Wake Forest University Health Science

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Microlipid with fish oil group

Microlipid group

Arm Description

This group will be given early enteral lipid supplementation with Microlipid and fish oil.

This group will be given early enteral lipid supplementation only with Microlipid.

Outcomes

Primary Outcome Measures

The Serum Biomarkers of Inflammatory Cytokines
Compare the serum biomarkers of inflammatory cytokines of the infants receiving ML/FO to the infants only receiving ML between the initial feeding after placement of an ostomy and reanastomosis
The Serum Biomarkers of Oxidative Stress
Compare the serum biomarkers of oxidative stress of the infants receiving ML/FO to the infants only receiving ML between the initial feeding after placement of an ostomy and reanastomosis

Secondary Outcome Measures

The Average Enteral Calorie (Total Calorie) Intake Before Reanast
To compare the average enteral calorie (total calorie) intake of infants receiving ML/FO to the group only receiving ML between the initial feeding after placement of an ostomy and reanastomosis
The Average Weight Gain (g/Day) After Reanastomosis
To compare the the average weight gain (g/day) of infants receiving ML/FO to the infants only receiving ML after reanastomosis

Full Information

First Posted
August 18, 2012
Last Updated
November 7, 2018
Sponsor
Wake Forest University
search

1. Study Identification

Unique Protocol Identification Number
NCT01674478
Brief Title
Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies
Acronym
EMLFO-2
Official Title
Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
October 2012 (Actual)
Primary Completion Date
March 17, 2015 (Actual)
Study Completion Date
March 17, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wake Forest University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Necrotizing enterocolitis (NEC) and spontaneous intestinal perforation (SIP) are common devastating gastrointestinal diseases in premature infants. These infants often need surgical intervention to remove the dead bowel and create temporary enterostomies, resulting in short bowel syndrome (SBS), a malabsorption state due to insufficient bowel length or dysfunction to digest and absorb nutrients adequately. These infants are often nourished primarily with parental nutrition (PN) which can lead to many complications including PN-associated liver disease. However, with enteral feeding, the remaining bowel can adapt somewhat to the shortened state, reducing the need for PN. Enteral fats appear to be the most trophic macronutrients with the long chain polyunsaturated fatty acids (LCPUFA) being the most beneficial in promoting bowel adaptation. Fish oil (FO), a main source of n-3 LCPUFA, has been shown to promote bowel adaptation. Microlipid (ML) primarily contains n-6 PUFA and has been found to decrease ostomy output and increase weight gain in some SBS infants. WThe investigators will soon have completed a randomized clinical trial (EMLFO trial) (WFUHS IRB00011501, NCT01306838) entitled "Early Supplementation of Enteral Lipid with Combination of Microlipid and Fish Oil in Infants with Enterostomies". The preliminary data suggest that (a) by supplementing enteral ML/FO, we were able to decrease the use of IL; (b) premature infants in the treatment group who received ML/FO achieved higher enteral calorie (% of total calorie) intake before reanastomosis and better weight gain (g/day) after reanastomosis than those who received routine care in control group; and (c) the direct bilirubin level before reanastomosis tended to be lower in the treatment group than the control group although the difference was not statistically significant. Because the intervention consisted of both an increase in enteral fat intake as well as a specific type of fat intake (i.e. FO), it is unclear whether improved outcomes in the ML/FO group are attributable to FO's anti-inflammatory effects or the increased fat intake. Therefore, the investigators have designed a next randomized clinical trial to compare ML alone versus ML plus FO. We hypothesize that as compared to ML alone, ML plus FO will result in decreased systemic inflammation, as indicated by blood levels of inflammation-related proteins and indicators of oxidative stress.
Detailed Description
In comparison to EMLFO trial, the EMLFO-2 study will modify the eligibility criteria to only enroll the infants who have birthweight equal to or less than 1250 g with a jejunostomy or ileostomy as the result of surgical treatment for small intestine perforation or NEC in order to increase the homogeneity of patient population.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prematurity, Intestine Perforation, Necrotizing Enterocolitis (NEC), Short Bowel Syndrome (SBS)
Keywords
NEC, SBS, enterostomy, fish oil, Microlipid, Intralipid,, enteral fat

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Microlipid with fish oil group
Arm Type
Experimental
Arm Description
This group will be given early enteral lipid supplementation with Microlipid and fish oil.
Arm Title
Microlipid group
Arm Type
Active Comparator
Arm Description
This group will be given early enteral lipid supplementation only with Microlipid.
Intervention Type
Dietary Supplement
Intervention Name(s)
Microlipid with fish oil
Intervention Description
Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
Intervention Type
Dietary Supplement
Intervention Name(s)
Microlipid
Intervention Description
A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
Primary Outcome Measure Information:
Title
The Serum Biomarkers of Inflammatory Cytokines
Description
Compare the serum biomarkers of inflammatory cytokines of the infants receiving ML/FO to the infants only receiving ML between the initial feeding after placement of an ostomy and reanastomosis
Time Frame
2 years and 5 months
Title
The Serum Biomarkers of Oxidative Stress
Description
Compare the serum biomarkers of oxidative stress of the infants receiving ML/FO to the infants only receiving ML between the initial feeding after placement of an ostomy and reanastomosis
Time Frame
2 years and 5 months
Secondary Outcome Measure Information:
Title
The Average Enteral Calorie (Total Calorie) Intake Before Reanast
Description
To compare the average enteral calorie (total calorie) intake of infants receiving ML/FO to the group only receiving ML between the initial feeding after placement of an ostomy and reanastomosis
Time Frame
2 years and 5 months
Title
The Average Weight Gain (g/Day) After Reanastomosis
Description
To compare the the average weight gain (g/day) of infants receiving ML/FO to the infants only receiving ML after reanastomosis
Time Frame
2 years and 5 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
2 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: infants (age range: newborn to ≤ 2-month-old) whose birth weight are ≤ 1250g; who are admitted to BCH NICU for surgical intervention for NEC or small intestine perforation and then to have a jejunostomy or ileostomy; who are expected to need full or partial PN for at least 21days from the day of ostomy placement; and who have received enteral feedings ≤ 4 days since ostomy placement. Exclusion Criteria: infant with birth weight > 1250g; infant with colostomy; infants with enterostomy but unable to obtain written informed consent from parent; presence of congenital liver, renal, or metabolic diseases or syndromes or perinatal asphyxia; ostomy caused by surgical treatment for a condition other than NEC or small intestine perforation; and unable to initiate enteral feeding for more than 28 days since ostomy placement.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Qing Yang, MD, PhD
Organizational Affiliation
WFUHS
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wake Forest University Health Science
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
20531250
Citation
Yang Q, Kock ND. Effects of dietary fish oil on intestinal adaptation in 20-day-old weanling rats after massive ileocecal resection. Pediatr Res. 2010 Sep;68(3):183-7. doi: 10.1203/PDR.0b013e3181eb2ee5.
Results Reference
background
PubMed Identifier
22447320
Citation
Yang Q, Lan T, Chen Y, Dawson PA. Dietary fish oil increases fat absorption and fecal bile acid content without altering bile acid synthesis in 20-d-old weanling rats following massive ileocecal resection. Pediatr Res. 2012 Jul;72(1):38-42. doi: 10.1038/pr.2012.41. Epub 2012 Mar 23.
Results Reference
background
PubMed Identifier
20980771
Citation
Yang Q, Welch CD, Ayers K, Turner C, Pranikoff T. Early enteral fat supplementation with microlipid(R) and fish oil in the treatment of two premature infants with short bowel. Neonatology. 2010;98(4):348-53. doi: 10.1159/000316067. Epub 2010 Oct 27.
Results Reference
result
Citation
Woods CW, Ayers K, Turner C, Pranikoff T and Qing Yang. A Novel Nutritional Approach to Prevent Parenteral Nutrition-Associated Cholestasis in Two Premature Infants with Short Bowel Syndrome. ICAN: Infant, Child, & Adolescent Nutrition 2013 5: 32-36.
Results Reference
result
PubMed Identifier
23453547
Citation
Yang Q, Ayers K, Chen Y, Helderman J, Welch CD, O'Shea TM. Early enteral fat supplement and fish oil increases fat absorption in the premature infant with an enterostomy. J Pediatr. 2013 Aug;163(2):429-34. doi: 10.1016/j.jpeds.2013.01.056. Epub 2013 Feb 28.
Results Reference
result

Learn more about this trial

Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies

We'll reach out to this number within 24 hrs